Présentation de l'entreprise
Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions within the United States market. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, a domain characterized by high capital intensity and a focus on novel drug discovery rather than established product revenue. As of the latest data, the company holds a market capitalization of $364.08M, while its annual revenue and employee count are not disclosed in the available financial records. These valuation figures indicate that the market prices the company based on its potential pipeline value rather than current operational profitability, reflecting the typical position of a clinical-stage entity where value is derived from future drug approvals rather than existing sales streams.
Santé financière
The financial statements reveal a revenue figure marked as N/A, a net income of $-236,928,000 over the trailing twelve months, and an EBITDA of $-235,948,000, illustrating a significant gap between top-line activity and bottom-line profitability driven by substantial operational expenses. The free cash flow stands at $-115,712,376, indicating that the company is consuming cash reserves to fund its research and development efforts, which limits immediate financial flexibility but is a standard characteristic of the early-phase biotechnology lifecycle. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a status that signifies the company has not yet generated sufficient commercial sales to cover its fixed and variable costs, resulting in a lack of positive contribution margins. On the balance sheet side, the company holds $182.53M in cash against $55.01M in debt, supported by a debt-to-equity ratio of 52.96, suggesting a capital structure that relies heavily on equity financing rather than leveraged debt. The current ratio of 5.87 demonstrates robust short-term liquidity, providing ample coverage for current liabilities despite the ongoing cash burn. Return on Equity is reported at -121.2% and Return on Assets at -58.1%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common scenario for firms in the pre-revenue growth phase.
Évaluation de la valorisation
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -2.16, implying that the market is pricing the stock based on future negative earnings expectations rather than historical profitability. The price-to-book ratio is established at 3.36, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the perceived value of its intellectual property and clinical pipeline. Alternative valuation measures such as the price-to-sales ratio, which is listed as N/A, and the EV/EBITDA of -1.00, suggest that traditional multiple-based comparisons with mature pharmaceutical peers are not applicable due to the absence of positive earnings and sales data. The stock has traded between a 52-week high of $3.65 and a 52-week low of $0.61, with the current share price situated within this volatile historical range. The beta value of 3.12 highlights that the stock exhibits high price volatility relative to the broader market, moving with significantly greater amplitude than the general index.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the absence of historical commercial sales data required to calculate year-over-year expansion metrics for a clinical-stage company. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it follows the standard biotechnology model of reinvesting all available capital and potential future earnings into research and development rather than distributing income to shareholders. Consequently, the growth and income profile is defined entirely by the progression of clinical trials and the eventual commercialization of navacaprant, rather than by current earnings expansion or dividend yield generation. The overall financial picture depicts a high-risk, high-potential investment vehicle where capital appreciation relies on successful clinical outcomes rather than current income generation or steady revenue growth.